- Home
- COLL vs PTA Comparison
COLL vs PTA Comparison
Compare COLL & PTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | PTA |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 984.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | COLL | PTA |
|---|---|---|
| Price | $21.84 | $17.54 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | ★ 751.9K | 255.8K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $780,567,000.00 | N/A |
| Revenue This Year | $7.25 | N/A |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $21.62 | $17.05 |
| 52 Week High | $50.79 | $20.70 |
Technical Indicators
Market Signals| Indicator | COLL | PTA |
|---|---|---|
| Relative Strength Index (RSI) | 30.33 | 36.87 |
| Support Level | $21.65 | N/A |
| Resistance Level | $23.69 | $19.70 |
| Average True Range (ATR) | 0.87 | 0.29 |
| MACD | 0.24 | -0.02 |
| Stochastic Oscillator | 17.87 | 31.49 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.